Oaktree Acquisition Corp. III Life Sciences Financials
This page shows Oaktree Acquisition Corp. III Life Sciences (OACCU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Oaktree Acquisition Corp. III Life Sciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Oaktree Acquisition Corp. III Life Sciences's current ratio of 1.19 is below the typical benchmark, resulting in a score of 19/100. However, the company holds substantial cash reserves (110% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
For every $1 of reported earnings, Oaktree Acquisition Corp. III Life Sciences generates $-0.06 in operating cash flow (-$422K OCF vs $7.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Oaktree Acquisition Corp. III Life Sciences reported $7.3M in net income in fiscal year 2025.
Cash & Balance Sheet
Oaktree Acquisition Corp. III Life Sciences held $1.4M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Capital Allocation
OACCU Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$457K | N/A | -$226K+16.4% | -$270K+39.3% | -$445K | N/A | -$48K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $1.4M | N/A | $2.0M+4.9% | $1.9M+13.0% | $1.7M | N/A | -$48K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OACCU Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Total Assets | $204.8M+0.8% | $203.1M+0.9% | $201.2M+1.0% | $199.2M+1.0% | $197.2M+1.0% | $195.3M | N/A |
| Current Assets | $1.4M-8.5% | $1.5M+4.5% | $1.5M-5.1% | $1.6M+5.3% | $1.5M-4.9% | $1.6M | N/A |
| Cash & Equivalents | $1.3M-11.0% | $1.4M+8.0% | $1.3M-4.1% | $1.4M+8.1% | $1.3M-5.6% | $1.4M | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $212.1M+1.0% | $209.9M+0.9% | $208.0M+1.1% | $205.7M+1.0% | $203.8M+1.2% | $201.3M | N/A |
| Current Liabilities | $1.6M+25.0% | $1.3M+5.9% | $1.2M+9.6% | $1.1M+5.7% | $1.1M+45.5% | $727K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$7.2M-6.7% | -$6.8M-0.1% | -$6.8M-3.4% | -$6.5M-0.3% | -$6.5M-7.3% | -$6.1M-26202.1% | -$23K |
| Retained Earnings | -$7.2M-6.7% | -$6.8M-0.1% | -$6.8M-3.4% | -$6.5M-0.3% | -$6.5M-7.3% | -$6.1M | N/A |
OACCU Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$158K-9.8% | -$144K-154.6% | -$57K+61.3% | -$146K-93.4% | -$76K+15.8% | -$90K | $0 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $250K | $0 | N/A | N/A | -$192.0M | $0 |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OACCU Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.7% | N/A | 1.0%+0.0pp | 0.9%+0.1pp | 0.8% | N/A | N/A |
| Current Ratio | 0.87-0.3 | 1.19-0.0 | 1.21-0.2 | 1.390.0 | 1.40-0.7 | 2.14 | N/A |
| Debt-to-Equity | -29.34+1.7 | -31.00-0.3 | -30.75+0.7 | -31.46-0.2 | -31.25+1.9 | -33.14 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Oaktree Acquisition Corp. III Life Sciences profitable?
Yes, Oaktree Acquisition Corp. III Life Sciences (OACCU) reported a net income of $7.3M in fiscal year 2025.
What is Oaktree Acquisition Corp. III Life Sciences's operating cash flow?
Oaktree Acquisition Corp. III Life Sciences (OACCU) generated -$422K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Oaktree Acquisition Corp. III Life Sciences's total assets?
Oaktree Acquisition Corp. III Life Sciences (OACCU) had $203.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Oaktree Acquisition Corp. III Life Sciences's current ratio?
Oaktree Acquisition Corp. III Life Sciences (OACCU) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.
What is Oaktree Acquisition Corp. III Life Sciences's debt-to-equity ratio?
Oaktree Acquisition Corp. III Life Sciences (OACCU) had a debt-to-equity ratio of -31.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oaktree Acquisition Corp. III Life Sciences's return on assets (ROA)?
Oaktree Acquisition Corp. III Life Sciences (OACCU) had a return on assets of 3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oaktree Acquisition Corp. III Life Sciences's cash runway?
Based on fiscal year 2025 data, Oaktree Acquisition Corp. III Life Sciences (OACCU) had $1.4M in cash against an annual operating cash burn of $422K. This gives an estimated cash runway of approximately 41 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Oaktree Acquisition Corp. III Life Sciences's debt-to-equity ratio negative or unusual?
Oaktree Acquisition Corp. III Life Sciences (OACCU) has negative shareholder equity of -$6.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are Oaktree Acquisition Corp. III Life Sciences's earnings high quality?
Oaktree Acquisition Corp. III Life Sciences (OACCU) has an earnings quality ratio of -0.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Oaktree Acquisition Corp. III Life Sciences?
Oaktree Acquisition Corp. III Life Sciences (OACCU) scores 3 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.